medigraphic.com
ISSN 1561-3011 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2014; 33 (2)

Risk factors and cardiovascular disease in recently diagnosed type 2 diabetics

Valdés RE, Camps AMC, Verdecia SR

Language: Spanish
References: 29
Page: 177-185
PDF size: 95.38 Kb.


ABSTRACT

Objective: identify the risk factors and the frequency of cardiovascular disease among persons recently diagnosed with type 2 diabetes mellitus.
Methods: a descriptive cross-sectional study was conducted with patients hospitalized in the Diabetes Care Center of Bayamo, Granma, from January 2011 to July 2012. The study universe was the 683 patients admitted to the institution during the period. The study sample was the 150 type 2 diabetics with less than 6 months since diagnosis.
Results: 100% of the patients had at least one cardiovascular risk. The most common were overweight and obesity in 135 cases (90.0%), metabolic syndrome in 100 (66.6%) and arterial hypertension in 99 (66.0%). At diagnosis, 24 patients (16%) had the following cardiovascular conditions: 11 (7.3%) ischemic cardiopathy, 4 (2.6%) stroke and 13 (8.6%) peripheral arterial disease. More than one complication was detected in four of them.
Conclusions: risk factors have a high frequency among type 2 diabetics from the territory. This may explain why a considerable proportion of cases already have cardiovascular complications at diagnosis.


REFERENCES

  1. American Diabetes Association: report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2007;24:S5-S20.

  2. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care. 2009;32(suppl 1):S13-61.

  3. Benjamin SM, Valdez R, Geiss LS, Rolka DB, Narayan KM. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. Diabetes Care. 2003;26:645-9.

  4. Björnholt J, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999;22:45-9.

  5. Méndez JD, Xie J, Aguilar M, Méndez V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem. 2010. [citado 15 Jun 2010]. Disponible en: http://www.springerlink.com/content/wmg173j7w459u483/

  6. Cooper-Dehoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8.

  7. DNE. Anuario Estadístico de Salud 2009. Ciudad de La Habana: MINSAP-DNE; 2011. 8. World Health Organization (WHO). Definition and classification of diabetes mellitus and complications. Report of WHO consultation. Part 1: Diagnosis and classification of Diabetes mellitus. World Health Organization. Department of Noncommunicable Desease Surveillance. Génova, 1999.

  8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-72.

  9. World Health Organization (WHO). Expert Committee Phycal Status. The use and interpretation of anthropometry. Geneva . WHO Technical Report Serie No 854;1995.

  10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

  11. Schettler G and Nüssel E. Cholesterol CHOP-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  12. Schettler G and Nüssel E. Triglycerides liquicolor GPO-PAP. Arb Med Loz Med Präv Med. 1975;10:25.

  13. Lópes-Virella M, Stone MF, Ellis S. Cholesterol determinations in HDL separated by three different methods. Clin Chem. 1977;23:882-5.

  14. Primer consenso cubano de dislipoproteinemias: Guía para la prevención, detección, diagnóstico y tratamiento. Rev Cubana Endocrinol. 2006;17(4):1-31.

  15. Escobar F. Pie diabético y factores de riesgo. Av Diabetol 1995;5:71-76.

  16. Ito H, Harano Y, Suzuky M, Hattori y, Takeuchi M, Inada H, et al. Risk factor analyses for macrovascular complication in nonobese NIDDM patients multiclinal study for diabetic macroangiopathy. Diabetes 1996;45 (Suppl 3):519-23.

  17. Guize L., Pannier B., Thomas F., Bean K., Jégo B., Benetos A. Recent advances in metabolic syndrome and cardiovascular disease. Arch Cardiovasc Dis. 2008;101:577-83.

  18. Salama Benarroch Isaac, Sánchez Gustavo Adolfo. Factores de riesgo y complicaciones crónicas en el diagnóstico reciente de la diabetes tipo 2. Rev Cubana Endocrinol [revista en la Internet]. 2001 Ago [citado 2012 Dic 21];12(2): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532001000200003&lng=es .

  19. Mata-Cases M, Fernández-Bertolín E, García-Durán M, Cos-Claramunt X, Pareja-Rossell C, Pujol-Ribera E. Prevalencia de enfermedad cardiovascular en personas recién diagnosticadas de diabetes mellitus tipo 2. Gac Sanit. 2009;23:133-8.

  20. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care. 2003;26:868-74.

  21. Festa A, Williams K, D'Agostino R, Wagenknecht LE, Haffner SM. The natural course of Beta Cell function in nondiabetic and diabetic individuals in the Insulin Resistance Atherosclerosis Study (IRAS). The Insulin Resistance Atherosclerosis Study Diabetes. 2006;55:1114_20.

  22. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007;99:6B-14B.

  23. Hypertension in Diabetes Study (HDS) (I). Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993; 11:309-17. 25. Spijkerman A.M., Henry R.M., Dekker J.M., et-al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practi the Hoorn Screening Study. J Intern Med. 2004;256:429-36.

  24. Arteagoitia J.M., Larranaga M.I., Rodríguez J.L., et-al. Incidence, prevalence and coronary heart disease risk level in known type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. Diabetologia. 2003;46:899-909.

  25. Valdés E, Bencosme N. Frecuencia de la hipertensión arterial y su relación con algunas variables clínicas en pacientes con diabetes mellitus tipo 2. Rev Cubana de Endocrinol. 2009;20(3):1561-2953.

  26. Swei A, Lacy F, Delano FA, Schmid-Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension. 1997;30:1628-33.

  27. Chobanian AV, Dzau VI. Renin angiotensin system and atherosclerotic vascular disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artyery disease. Vol 1. Philadelphia: Lipincott-Raven; 1996. p.237-42.

  28. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease. 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115:450-8.

  29. Norderstgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting tryglycerides and risk of myocardial infarction, ischemic heart disease and death in men and women. JAMA. 2007;298;299-308.




2020     |     www.medigraphic.com